Preparing clinical documentation for translation is not an administrative step. It is a technical decision with direct consequences for the quality of the final output, delivery timelines, and regulatory acceptance. Sponsors who hand over documentation without prior preparation routinely face costly revisions, submission delays, and terminology inconsistencies that undermine coherence across the trial master file.
This guide is written for regulatory affairs teams, clinical project managers, and clinical operations leads who want to optimise the process before sending any file to a translation provider.
What to include in the initial briefing
The briefing is the foundation. An incomplete briefing is the most common cause of problems throughout the project. Before sending any document, the following elements should be defined clearly:
- Language pairs: specify the source language and all target languages. For multinational trials, the list may include ten or more languages, each with its own regulatory and linguistic requirements.
- Regulatory purpose: indicate whether documents are destined for submission to the EMA, national competent authorities, local IRBs or ethics committees, or for internal use only.
- Certification requirements: some documents require certified or sworn translation to be accepted by specific authorities. This requirement must be clarified at the outset, not after the first draft is delivered.
- Available reference materials: glossaries, translation memories from previous projects, style guides, and approved term lists should be shared before work begins.
- Deadlines and priorities: in clinical trials, not all documents carry the same urgency. Identifying which files sit on the critical submission path allows the provider to allocate resources efficiently.
Technical preparation of files
File format has a direct impact on cost, timeline, and translation quality. Documents delivered in non-editable formats, such as scanned PDFs, require optical character recognition before translation can begin. This introduces errors, increases effort, and extends timelines.
Practical rules for technical preparation:
- Deliver editable files: Word, Excel, PowerPoint, or XML are preferable to PDF. If only a PDF is available, confirm it is a text-based PDF rather than an image scan.
- Lock the layout before starting: changes to the source document during translation require rework. Freezing the version before the project begins avoids costly amendments.
- Identify non-translatable elements: clinical data tables, compound names, dose designations, ICMJE-formatted references, and standardised regulatory abbreviations (ICH, CIOMS) should not be translated. Marking these in the document saves time and prevents errors.
- Check internal terminology consistency: if the same concept appears under two different labels within the same document, the translation will reproduce that inconsistency. Pre-translation terminology review is the sponsor's responsibility.
Managing glossaries and translation memories
In clinical trials, terminology consistency across documents is not a stylistic preference. It is a regulatory requirement. The same term must carry the same translation in the protocol, the informed consent form, the DSMB charter, safety reports, and every other submitted document.
The most effective way to achieve this consistency is to invest in translation assets from the start of the programme:
- Study glossary: a bilingual or multilingual list of the protocol's key terms, approved by the sponsor's medical and scientific team. It should cover the investigational medicinal product name (INN and brand name), inclusion and exclusion criteria, primary and secondary endpoints, and adverse event terminology.
- Translation memory: a repository of approved translations from previous projects within the same programme or compound. It allows validated segments to be reused, reduces inconsistencies, and optimises resources on high-volume projects.
- Style guide: defines register preferences, capitalisation rules, approved abbreviations, and numeric formatting conventions. Particularly relevant for patient-facing documents such as the informed consent form, where language must be accessible to a lay audience.
The translation of clinical trial protocols for regulatory submission demands exactly this level of prior preparation to meet submission timelines and the quality standards expected by competent authorities.
Classifying documents by criticality level
Not all documents in a clinical trial carry the same regulatory weight, and not all errors carry the same risk. Classifying the document portfolio before translation allows the appropriate level of review to be assigned to each type.
A practical classification follows three levels:
High criticality: study protocol and amendments, informed consent form, Investigator's Brochure, regulatory submission dossiers, safety reports. These documents require a rigorous review process: a specialist translator, an independent reviewer, and quality verification. Any error can have direct consequences for participant safety or the validity of the submission.
Intermediate criticality: site-adapted SOPs, investigator training materials, ethics committee submission letters, trial management documents. Professional quality is required, but the risk associated with an error is less immediate.
Reference and internal-use documents: supporting literature, archive documentation, preliminary reports, internal correspondence. In these cases, a machine translation post-editing approach with selective human review may be appropriate, provided the document is not intended for regulatory submission or communication with participants.
This classification logic applies equally to pharmaceutical translation programmes and to any clinical trial document portfolio.
How M21Global supports clinical trial sponsors
M21Global has worked with sponsors and CROs on clinical and regulatory translation projects for over 20 years. The team is familiar with the documentary requirements of ICH E6(R3), the expectations of national competent authorities across its operating markets, and the submission processes at the EMA. For high-criticality documents, the workflow follows ISO 17100:2015, audited by Bureau Veritas, with three linguists and post-delivery revision rounds. For higher-volume, lower-criticality material, the IAH+ approach combines machine translation with selective human review. If a team needs support structuring the translation process for an ongoing or upcoming trial, M21Global is available for a technical conversation with no commitment required.
Related Services
Request a free medical translation quote
- Request a free medical translation quote
- Medical Device Documentation Translation Mdr Compliance
- Translating Clinical Trial Protocols Regulatory Submission
- Drug Labeling Translation
Frequently Asked Questions
Which clinical trial documents require certified translation?
It depends on the jurisdiction and receiving authority. Documents submitted to national competent authorities or ethics committees often require certified translation. Sponsors should verify the specific requirements of each authority before the project begins.
What is a translation memory and why is it useful in clinical trials?
A translation memory is a repository of previously translated and approved text segments. In clinical trials, it allows validated translations from earlier documents in the same programme to be reused, ensuring terminology consistency across the protocol, informed consent form, and safety reports.
Can clinical documents be translated from PDF files?
It is possible, but not the most efficient option. Image-based PDFs require optical character recognition before translation can begin, which can introduce errors and extend timelines. Editable formats such as Word or XML are preferable wherever available.
How do you maintain terminology consistency across a multilingual multinational trial?
The most effective approach is to create a multilingual study glossary before translation begins, approved by the sponsor's medical team. The glossary should cover key protocol terms and be shared with all translation providers involved in the programme.
What level of review is appropriate for the informed consent form?
The informed consent form is a high-criticality document with direct implications for participant rights and safety. It requires a rigorous review process with a specialist translator and an independent reviewer, and should undergo back-translation where required by the protocol or the study ethics board.
